MedChemComm
Research Article
periodontal disease through the commensal microbiota and
complement, Cell Host Microbe, 2011, 10, 497–506, DOI:
10.1016/j.chom.2011.10.006.
25 K. M. Carlson-Banning, A. Chou, Z. Liu, R. J. Hamill, Y. Song
and L. Zechiedrich, Toward repurposing ciclopirox as an
antibiotic against drug-resistant Acinetobacter baumannii,
Escherichia coli, and Klebsiella pneumoniae, PLoS One,
2013, 8, e69646, DOI: 10.1371/journal.pone.0069646.
26 F. Imperi, F. Massai, C. Ramachandran Pillai, F. Longo, E.
Zennaro, G. Rampioni, P. Visca and L. Leoni, New life for an
old drug: the anthelmintic drug niclosamide inhibits
Pseudomonas aeruginosa quorum sensing, Antimicrob.
Agents Chemother., 2013, 57, 996–1005, DOI: 10.1128/
AAC.01952-12.
12 G. Hajishengallis, R. P. Darveau and M. A. Curtis, The
keystone-pathogen hypothesis, Nat. Rev. Microbiol., 2012, 10,
717–725, DOI: 10.1038/nrmicro2873.
13 R. J. Lamont, A. Chan, C. M. Belton, K. T. Izutsu, D. Vasel
and A. Weinberg, Porphyromonas gingivalis invasion of
gingival epithelial cells, Infect. Immun., 1995, 63, 3878–3885.
14 A. Mombelli and L. P. Samaranayake, Topical and systemic
antibiotics in the management of periodontal diseases, Int.
Dent. J., 2004, 54, 3–14.
27 F. Imperi, F. Massai, M. Facchini, E. Frangipani, D. Visaggio,
L. Leoni, A. Bragonzi and P. Visca, Repurposing the
15 A. Mombelli, A. Almaghlouth, N. Cionca, D. S. Courvoisier
and C. Giannopoulou, Differential benefits of amoxicillin-
metronidazole in different phases of periodontal therapy in
antimycotic
drug
flucytosine
for
suppression
of
Pseudomonas aeruginosa pathogenicity, Proc. Natl. Acad.
Sci. U. S. A., 2013, 110, 7458–7463, DOI: 10.1073/
pnas.1222706110.
a
randomized controlled crossover clinical trial,
J. Periodontol., 2015, 86, 367–375, DOI: 10.1902/
jop.2014.140478.
28 D. T. Scow, G. K. Luttermoser and K. S. Dickerson,
Leukotriene inhibitors in the treatment of allergy and
asthma, Am. Fam. Physician, 2007, 75, 65–70.
16 A. Mombelli, N. Cionca, A. Almaghlouth, A. Cherkaoui, J.
Schrenzel and C. Giannopoulou, Effect of periodontal
therapy with amoxicillin-metronidazole on pharyngeal car-
riage of penicillin- and erythromycin-resistant Viridans strep-
tococci, J. Periodontol., 2016, 87, 539–547, DOI: 10.1902/
jop.2015.150494.
29 S. Schierle, C. Flauaus, P. Heitel, S. Willems, J. Schmidt, A.
Kaiser, L. Weizel, T. Goebel, A. S. Kahnt, G. Geisslinger, D.
Steinhilber, M. Wurglics, G. E. Rovati, A. Schmidtko, E.
Proschak and D. Merk, Boosting anti-inflammatory potency
of zafirlukast by designed polypharmacology, J. Med. Chem.,
2018, 61, 5758–5764, DOI: 10.1021/acs.jmedchem.8b00458.
30 A. A. Martinez, B. A. Espinosa, R. N. Adamek, B. A. Thomas,
J. Chau, E. Gonzalez, N. Keppetipola and N. T. Salzameda,
Breathing new life into West Nile virus therapeutics;
discovery and study of zafirlukast as an NS2B-NS3 protease
inhibitor, Eur. J. Med. Chem., 2018, 157, 1202–1213, DOI:
10.1016/j.ejmech.2018.08.077.
17 A. D. Haffajee, S. S. Socransky and J. C. Gunsolley, Systemic
anti-infective periodontal therapy. A systematic review, Ann.
Periodontol.,
2003,
8,
115–181,
DOI:
10.1902/
annals.2003.8.1.115.
18 R. P. Ellen and C. A. McCulloch, Evidence versus empiricism:
rational use of systemic antimicrobial agents for treatment
of periodontitis, Periodontol. 2000, 1996, 10, 29–44, DOI:
10.1111/j.1600-0757.1996.tb00067.x.
19 T. E. Rams, J. E. Degener and A. J. van Winkelhoff,
Antibiotic resistance in human chronic periodontitis
microbiota, J. Periodontol., 2014, 85, 160–169, DOI: 10.1902/
jop.2013.130142.
31 L. Pinault, J. S. Han, C. M. Kang, J. Franco and D. R.
Ronning, Zafirlukast inhibits complexation of Lsr2 with DNA
and growth of Mycobacterium tuberculosis, Antimicrob. Agents
Chemother., 2013, 57, 2134–2140, DOI: 10.1128/AAC.02407-
12.
32 E. Gerits, I. Van der Massen, K. Vandamme, K. De Cremer,
K. De Brucker, K. Thevissen, B. P. A. Cammue, S. Beullens,
M. Fauvart, N. Verstraeten, J. Michiels and M. Roberts, In
vitro activity of the antiasthmatic drug zafirlukast against
the oral pathogens Porphyromonas gingivalis and
Streptococcus mutans, FEMS Microbiol. Lett., 2017, 364,
fnx005, DOI: 10.1093/femsle/fnx005.
33 C. L. Ancell, I. Derrick, J. D. Moseley and J. A. Stott,
Investigation into the acidification process of zafirlukast
nitroacid leads to a surprising improvement in product
quality, Org. Process Res. Dev., 2004, 808–813, DOI: 10.1021/
op049911+.
34 K. Srinivas, N. Srinivasan, M. R. Krishna, A. R. Reddy, M.
Arunagiri, R. Lalitha, K. S. R. Reddy, P. P. Reddy, M. K.
Kumar and M. S. Reddy, A novel and efficient route to
zafirlukast, Org. Process Res. Dev., 2004, 8, 952–954, DOI:
10.1021/op049869i.
20 T. T. Ashburn and K. B. Thor, Drug repositioning:
identifying and developing new uses for existing drugs, Nat.
Rev. Drug Discovery, 2004, 3, 673–683, DOI: 10.1038/nrd1468.
21 C. R. Chong and D. J. Sullivan, , Jr., New uses for old drugs,
Nature, 2007, 448, 645–646, DOI: 10.1038/448645a.
22 A. Rangel-Vega, L. R. Bernstein, E. A. Mandujano-Tinoco,
S. J. Garcia-Contreras and R. Garcia-Contreras, Drug
repurposing as an alternative for the treatment of
recalcitrant bacterial infections, Front. Microbiol., 2015, 6,
282, DOI: 10.3389/fmicb.2015.00282.
23 L. C. Antunes, F. Imperi, F. Minandri and P. Visca, In vitro
and in vivo antimicrobial activities of gallium nitrate against
multidrug-resistant Acinetobacter baumannii, Antimicrob.
Agents Chemother., 2012, 56, 5961–5970, DOI: 10.1128/
AAC.01519-12.
24 C. Attila, A. Ueda and T. K. Wood, 5-Fluorouracil reduces
biofilm formation in Escherichia coli K-12 through global
regulator AriR as an antivirulence compound, Appl. Micro-
biol. Biotechnol., 2009, 82, 525–533, DOI: 10.1007/s00253-
009-1860-8.
35 G. Goverdhan, A. R. Reddy, A. Sampath, K. Srinivas, V.
Himabindu and G. M. Reddy, An improved and scalable
This journal is © The Royal Society of Chemistry 2019
Med. Chem. Commun.